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Abstract
Introduction Influenza virus is a potential cause of severe
disease in the immunocompromised. X-linked agammaglobu-
linemia (XLA) is a primary immunodeficiency characterized
by the lack of immunoglobulin, B cells, and plasma cells,
secondary to mutation in Bruton’s tyrosine kinase (Btk) gene.
Btk is expressed in both B and dendritic cells (DC). However,
little is known about the immune response of DC and Tcells to
influenza virus in XLA patients.
Methods The in vitro maturation and antigen presenting
function of monocyte-derived immature DC (imDC) from
12 XLA patients and 23 age-matched normal controls in
response to influenza virus were examined. Influenza virus-
specific CD4 and CD8 T cell responses in the patients and
controls were further determined after administration of
inactivated trivalent influenza vaccine.
Results imDC from XLA patients had normal maturation
based on major histocompatibility complex (MHC)-I, MHC-
II, CD83 and CD86 expression, and interferon (IFN)-α and
interleukin-12 production upon influenza virus stimulation.
They also had a normal capacity to induce allogeneic T cell
proliferation in response to influenza virus. TIV was well
tolerated in XLA patients. Influenza virus-specific
CD4+IFN-γ+ and CD8+ IFN-γ+ T cells and HLA-A2/
M158–66-tetramer
+ CTLs could be induced by TIV in
XLA patients, and the levels and duration ofmaintaining these
virus-specific cells in XLA patients are comparable to that in
normal controls.
Conclusion We demonstrated for the first time that XLA
patients have fully competent DC and Tcell immune responses
to influenza virus. TIV is safe and could be an option for
providing T cell-mediated protection against influenza virus
infection in XLA patients.
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Influenza virus is a cause of substantial morbidity and
mortality worldwide. Seasonal and pandemic influenza has
posed many challenges for our community [1]. Children and
the immunocompromised have high risks for influenza virus
infection. X-linked agammaglobulinemia (XLA) is an X-
chromosome linked recessive primary immunodeficiency
characterized by the lack of immunoglobulin, B cells, and
plasma cells, secondary to mutation in the Bruton’s tyrosine
kinase (Btk) gene [2, 3]. Due to the deficiency of humoral
immunity, cellular immune response becomes critical for
these patients to control infections, including influenza.
T cell-mediated cellular immunity against virus
depends on the activation of T cells by professional
antigen presenting cells (APC), such as dendritic cells
(DC). Btk is a member of the Tec family of protein
tyrosine kinases, constitutively expressed in all hematopoietic
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cells including DC and monocytes, except T and natural killer
cells [4, 5]. Multiple defects in the development and function
of DC in XLA patients and Btk-deficient mice have been
reported [6–11]. However, it is still not clear whether DC from
XLA patients have defect in their maturation and cytokine
production during influenza virus infection.
Very few but contradictory data on the T cell function in
XLA patients and Btk-deficient mice were reported. One
earlier study described an impaired delayed cutaneous hyper-
sensitivity reaction in XLA patients [12]. However, another
study of 5 XLA patients indicated that their T cell activity and
cytokine production are normal in terms of Tcell proliferation,
interleukin (IL)-2, interferon (IFN)-γ, and IL-4 production in
response to either various mitogens or tetanus toxoid [13]. In
contrast, it has been demonstrated that there is predominant
Th1 response in a cohort of 6 XLA patients [14]. Whether
XLA patients have impaired T cell function, secondary to the
deficiency of B cells or the defect of DC to influenza virus,
remains unknown.
Recently, we summarized the clinical characteristics
and genotype–phenotype correlation in 62 XLA patients
diagnosed by our laboratory with confirmation of the
mutations in Btk gene over the past 20 years [15, 16].
In the present study, using immature monocyte-derived
DC (imDC) from XLA patients, we determined DC
maturation and antigen presenting ability in response
to influenza virus as defined by phenotype, cytokine
production, and mixed lymphocyte reaction in vitro.
The influenza virus-specific CD4+ and CD8+ T cell
responses were further determined in XLA patients after
administration of inactivated influenza vaccine.
Methods
Subjects
Twelve XLA patients aged 14–31 years old and 23 age-
matched healthy volunteers were recruited before the 2008
influenza season and vaccinated with one dose of 2008–
2009 seasonal trivalent influenza vaccine comprised of
A/Brisbane/59/2007 (H1N1)-like, A/Brisbane/10/2007
(H3N2)-like, and B/Florida/4/2006-like strains manufactured
by GlaxoSmithKline Biologicals. For patients, the exclusion
criteria include known allergy to egg or component of the
influenza vaccine, receipt of any other vaccinewithin 1month.
For healthy volunteers, the exclusion criteria include any
serious infection at time of vaccination; known or suspected
impairment of immunologic function including, but not limited
to, clinically significant liver disease, diabetes mellitus,
moderate to severe kidney impairment, and autoimmune
disease; use of immunosuppressive medication; known
allergy to egg or component of the influenza vaccine;
and receipt of any other vaccine within 1 month. All patients
were receiving regular intravenous immunoglobulin (IVIG)
replacement therapy at 4-week intervals. The first blood draw
was taken prior to the infusion of IVIG, and the subsequent
blood draw was taken at indicated time after vaccination. The
research protocol was approved by the Institutional Review
Board of the University of Hong Kong/Hospital Authority
Hong Kong West Cluster.
Generation of imDC In Vitro
Monocytes and CD3+ T cells were isolated from PBMCs
by using anti-CD14 and anti-CD3 microbeads respectively
(Miltenyi Biotec, Germany) [17, 18]. The purity of isolated
CD14+ cells and CD3+ T cells was consistently ranging from
93% to 97%, as determined by flow cytometry. Monocytes
were cultured in RPMI supplemented with 10% human AB
serum, 10 ng/ml IL-4, and 50 ng/ml GM-CSF (Peprotech,
Rocky Hill, NJ, USA) for 7 days to generate imDC as we
described before [19, 20].
Phenotypic Analysis and Cytokine Measurement
Influenza A virus H1N1 (A/HK/54/98) was heat-inactivated
at 56°C for 30 min. imDC were incubated with H1N1 at
multiplicity of infection (MOI) of 1 in the absence of human
AB serum. After 1 h of viral adsorption, the culture was
supplemented with 10% human AB serum. After 24 h
of culture with virus, imDC were collected and analyzed
by immunofluorescent staining using mAbs PE/Cy5
anti-major histocompatibility complex (MHC)-I, APC
anti-CD83, and PE anti-CD86 (Biolegend, San Diego,
CA, USA), fluorescein isothiocyanate (FITC) anti-MHC-II
(BDPharmingen, San Jose, CA,USA) to determine phenotypic
maturation with flow cytometer. Supernatants were collected
and the concentrations of IL-12 and IFN-αwere determined by
Human IL-12 DuoSet (R&D system, Minneapolis, MN,
USA) and Verikine™ Human IFN-α ELISA Kit (PBL
InterferonSource, Piscataway, NJ, USA), respectively.
Mixed Lymphocyte Reaction
Allogeneic peripheral CD3+ Tcells were cultured in triplicate in
a 96-well, flat-bottomed microplate with different numbers of
irradiated (30 Gy) virus-treated imDC (DC/T cells ratio of
1:1,000, 1:100, or 1:10). [3H]-Thymidine was added to the
wells 18 h before the end of 6 days culture, and its incorporation
was measured to determine cell proliferation as described pre-
viously [21] with incorporation expressed as the mean ± SEM
counts per minute of three wells.
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Influenza Virus-Specific T Cell Immunity
The memory/effector influenza virus-specific CD4 and
CD8 T cells were measured by whole blood intracellular
cytokine staining assay as we established before
[22–24]. Fresh, heparinized whole blood was incubated
with 2008–2009 trivalent seasonal influenza vaccine at a
final concentration of 4.0 μg/ml. The negative control
was phosphate-buffered saline (PBS). Co-stimulation
was done with anti-CD28 and anti-CD49d mAbs
(3 μg/ml; BD Biosciences, San Jose, CA, USA). After
2 h of incubation, brefeldin A was added at a final
concentration of 10 μg/ml, and the blood samples were
incubated for an additional 4 h. Following 6 h of
incubation, red blood cells were lysed and fixed by
FACS lysing solution (BD Biosciences). The fixed cells
were washed; stained with mAb mixture consisting of
anti-CD3-PE, anti-CD4-PE-Cy5, and anti-CD8-APC (BD
Biosciences, San Jose, CA, USA) for surface markers;
and then cells were permeabilized and stained with IFN-γ-
FITC intracellularly. Isotype-matched control mAbs of irrele-
vant specificity were included in all experiments [25, 26]. For
tetramer analysis, PBMCs were incubated with anti-CD3,
anti-CD8, and HLA-A2/M158–66 tetramer (Beckman Coulter)
for 30 min [23]. HLA-A*0201 phenotype screening was done
with primary MAbs MA2.1 (HLA-A2 and B17) or BB7.2
(HLA-A2 and Aw69) (ATCC) and secondary FITC goat-anti-
mouse IgG. Samples were collected 2–5×105 events for each
sample with FACSAria flow cytometer (BD Biosciences).
Data were prepared for statistical analysis using FLOW JO
software (Tree Star, San Carlos, CA, USA).
Statistical Analysis
Data were expressed as mean ± SEM. Statistical analysis
was performed by Student’s paired t test or one-way
ANOVA with a multiple comparison test using Prism 5
(GraphPad Software). P<0.05 was considered significant.
Results
The Differentiation and Maturation of imDC in XLA
Patients Upon Influenza Virus Stimulation
imDC were generated in vitro from purified blood
monocytes from 12 XLA patients and 23 age-matched
healthy donors in the presence of IL-4 and GM-CSF. As
shown in Fig. 1, the monocytes from XLA patients and
normal controls differentiated into imDC after 7 days of
culture. The imDC derived from monocytes of patients
expressed similar level of MHC-I, MHC-II, and CD83
but lower CD86 level compared to that of normal
controls (Fig. 1a, b). After 24 h stimulation with influ-
enza virus, significant upregulation of CD83 and CD86
expressions was observed in imDC from patients
(Fig. 1b). In contrast, MHC-I, MHC-II, CD83, and
CD86 molecules in imDC from normal controls were
all upregulated by stimulation with influenza virus
(Fig. 1b). Importantly, the expression level of these four
molecules in imDCs from patients after stimulation with
influenza virus was comparable to that from normal
controls (Fig. 1b). These data indicated that imDC from
XLA patients have normal differentiation and maturation
upon influenza virus stimulation in terms of the
phenotype.
Cytokine Production of DC in XLA Patients Upon Influenza
Virus Stimulation
To further confirm whether the mature phenotype of imDC
from XLA patients was associated with normal function of
DC in terms of cytokine production, the production of IFN-α
and IL-12 in imDC upon influenza virus stimulation was
examined. As shown in Fig. 2, influenza virus significantly
enhanced the production of IFN-α in imDC from either
patients or normal controls as compared to mock-treated
imDC. However, influenza virus did not induce IL-12
production in imDC from patients or normal controls.
The levels of IFN-α and IL-12 produced by imDC from
patients were similar to that from normal controls before
or after influenza virus stimulation. These data indicated
that imDC from XLA patients has normal function in
response to influenza virus.
T Cell Stimulatory Ability of Influenza Virus-Treated DC
in XLA Patients
To determine the T cell stimulatory capacity of influenza virus-
treated imDC from XLA patients, allogeneic naïve CD3+ T
cells were stimulated with influenza virus- or mock-treated
imDC from XLA patients and normal controls. As shown in
Fig. 3, influenza virus-treated imDC from patients or normal
controls induced allogeneic naïve CD3+ Tcell proliferation in a
dose-dependent manner. There was no significant difference
between imDC from patients and normal controls in their
capacities to induce allogeneic T cell proliferation. These data
suggest that imDC from XLA patients have a normal capacity
to induce T cell responses to influenza viruses.
Safety of TIV in XLA Patients
Twelve XLA patients and 23 age-matched normal controls
were administrated with one dose of TIV intramuscularly. TIV
was well tolerated in both groups. No obvious adverse events,
including induration, redness, ecchymosis, and shivering,
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were reported during the first month after vaccination in both
patients and normal controls.
Induction of Influenza Virus-Specific T Cells by TIV
in XLA Patients
To determine influenza virus-specific T cell immunity in XLA
patients in vivo, the frequencies of peripheral blood influenza-
specific CD4+ and CD8+ T cells were assessed in these XLA
patients and normal controls before and after 1 week, 1 month,
3 months, and 6 months of TIV vaccination using vaccine as an
antigenic stimulus in vitro. As shown in representative studies
from a single normal adult donor (Fig. 4a), a discrete subset of
CD4+ or CD8+ T cells expressing IFN-γ were generated
after incubation with influenza vaccine antigen. Only
cells with IFN-γ expression were considered as true
positive influenza-specific CD4+ or CD8+ T cells, as
previously described [23, 24]. Frequencies of IFN-γ+CD4+
or IFN-γ+CD8+ T cells detected after addition of PBS buffer
were very low indicating the antigen-specificity of this
response.
In both XLA patients and normal controls, the frequency
of influenza-specific CD4+ T cells gradually increased from
1 week to 6 months post-vaccination and reached peak
levels at months 3 and 6 post-vaccination (Fig. 4b). To
compare the induction of influenza-specific CD4+ T cells
between patients and normal controls after immunization,
we evaluated the fold increase of influenza-specific CD4+ T
Fig. 1 The differentiation and
maturation of imDC in XLA
patients upon influenza virus
stimulation. Monocyte-derived
imDC from XLA patients
(n012) and normal controls
(n023) were treated with heat
killed H1N1 (MOI 0 1) for
24 h. Surface expressions of
MHC-I, MHC-II, CD83, and
CD86 were examined by flow
cytometry. a Histogram showed
the representative data of the
increase in phenotype
expressions after virus
stimulation; b bar chart showed
the mean fluorescent intensity
of the phenotype expression.
Data represented as mean ±
SEM. *p<0.05; **p<0.01
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cells from the basal level at the time of pre-vaccination. As
shown in Fig. 4c, the fold increase of influenza-specific CD4+
T cells in both patients and normal controls is comparable at
each time point post-vaccination, indicating XLA patients had
normal CD4+ T cell responses to influenza vaccine.
Similarly, influenza-specific CD8+ Tcells were also induced
by vaccine in XLA patients. The frequency of influenza-
specific CD8+ T cells gradually increased from 1 week to
6 months post-vaccination and reached a peak level at month
6 post-vaccination in both patients and normal controls
(Fig. 4b). For the fold increase of influenza-specific CD8+ T
cells from the basal level, there was no significant difference
between patients and normal controls at each time point post-
vaccination (Fig. 4c). This result suggests that XLA patients
had normal CD8+ T cell responses to TIV.
Induction of Influenza Virus M158–66 Epitope-Specific
Memory CTLs by TIV in XLA Patients
To further evaluate influenza virus-specific CD8+ cell
immunity in XLA patients in vivo, the frequencies of
peripheral blood influenza virus M158–66 epitope-specific
memory CTLs were assessed in HLA-A2-positive XLA
patients and normal controls. HLA-A2/M158–66-tetramer
+
CD8+ T cells from PBMCs isolated from seven HLA-
A2-positive XLA patients and 14 HLA-A2-positive normal
controls before and after TIV vaccination were analyzed.
Among them, one out of seven patients and two out of 14
normal individuals had detectable HLA-A2/M158–66-tetramer
+
CTLs before immunization (Fig. 5). After influenza
vaccination, the frequency of HLA-A2/M158–66-tetramer
+
CTLs was increased from week 1 to month 3 post vaccination
and dropped to the basal level after 6 months of vaccination in
patient and one normal control, whereas the frequency of
HLA-A2/M158–66-tetramer
+ CTLs maintained up to
6 months post-vaccination in another normal control.
These results indicated that TIV can induce CTL response in
both XLA patient and normal control although the duration
for maintain CLTs may varied among different cases (Fig. 5).
Discussion
In this study, using imDC from XLA patients, we first
showed that these imDC had normal maturation and
antigen presenting function in response to influenza
virus in vitro. By administration of TIV, we further
demonstrated that XLA patient had normal influenza
virus-specific CD4+ and CD8+ T cell responses in vivo.
This, to the best of our knowledge, is the first time to report
that XLA patient had a fully competent DC and Tcell immune
response to influenza virus.
Fig. 2 Cytokine production in DC in XLA patients upon influenza virus
stimulation. Monocyte-derived imDC from XLA patients (n012) and
normal controls (n023) were treated with heat killed H1N1 (MOI 0 1)
for 24 h. The concentrations of IFN-α and IL-12 in culture supernatant
was determined by ELISA. Data represented as mean ± SEM. NS no
significant difference; *p<0.05; **p<0.01; ***p<0.001
Fig. 3 T cell stimulatory ability of influenza virus-treated DC in XLA
patients.Monocyte-derived imDC fromXLA patients (n012) and normal
controls (n023) were treated with heat killed H1N1 (MOI 0 1) or mock
for 24 h. Cells were then irradiated and co-cultured with allogeneic
purified CD3+ T at different DC/T ratio for 6 days. The proliferative
responses of CD3+ T cells were measured by [3H]-thymidine incorpora-
tion assay. Data represented as mean ± SEM. ***p<0.001
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As Btk gene is constitutively expressed in DC and
monocytes, it is believed that the deficiency of Btk may
affect the maturation and function of DC. Indeed, Btk has
been demonstrated to be involved in toll-like receptor (TLR)
signaling [7, 9, 10]. However, the data from different cohorts
of XLA patients were not consistent. One study in a cohort of
eight XLA patients indicated that imDC from XLA patients
had less phenotypic maturation based on CD83 expression
and TNF-a production than controls, whereas the productions
of IL-6 and IL-12 in patients were comparable to that in
controls [27]. Other two studies, one in a cohort of five
XLA patients and another one in a cohort of six XLA patients,
showed that DC from XLA patients had normal phenotypic
maturation and antigen presenting function and no defect in
the production of IL-10 and IL-12 in response to stimulation
of TLR1/2, 2/6, 3, 4, and 5 but display impaired TLR8-
Fig. 4 Induction of influenza virus-specific T cells by TIV in XLA
patients. a Representative results of influenza-specific expression in
CD4+IFN-γ+ and CD8+ IFN-γ+ T cells from a normal individual after
3 month of TIV vaccination were shown. b The frequency of
CD4+IFN-γ+ and CD8+ IFN-γ+ T cells in the peripheral blood from
XLA patients (n012) and normal controls (n023) before and after TIV
vaccination. c The fold increase of influenza-specific CD4+IFN-γ+ and
CD8+ IFN-γ+ T cells from the basal level in XLA patients (n012) and
normal controls (n023). NS no significant difference
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mediated IL-6 and TNF-α production and TLR2- and TLR4-
mediated TNF-α and IL-1β production [6, 10]. Here, we
demonstrated that, although the CD86 expression in imDC
of XLA patients was also lower than that in normal controls,
imDC from XLA patients have normal maturation based on
phenotype (MHC-I, MHC-II, CD83, and CD86) expressions.
In addition, imDC in XLA patients have normal ability to
produce the major anti-viral cytokine IFN-α upon influenza
virus stimulation. Importantly, influenza virus-treated DC
have also showed a normal capacity to induce allogeneic T
cell proliferation.
The reason for the difference of DC maturation remains
unknown. Bayry et al. reported that the maturation of DC
from XLA patients in the presence of their autologous
plasma was severely impaired [28]. When reconstitution of
patients’ plasma with IVIG corresponding to the concentration
reached in patients’ plasma immediately following infusion or
with natural anti-CD40 IgG from IVIG, it could restore some of
the defects of DC maturation [28]. This suggests that the
impaired maturation of DC in XLA patients may be related
with the deficiency of circulating natural antibodies, especially
natural IgG to CD40. Since the blood samples from XLA
patients were taken prior to the infusion of IVIG, their autolo-
gous plasma may only have very low levels of the natural
antibodies. Therefore, Batry’s study found a severe impairment
of DCmaturation. In contrast, our current study and others used
normal human AB serum or fetal bovine sera for the culture of
DC, thus found a normal maturation of DC in XLA patients.
Whether B cells can regulate T cell-mediated immune
responses is still controversial. Some studies showed
that B cells were dispensable for the generation and
maintenance of antigen-specific T cell responses [29,
30], whereas other studies have demonstrated that B
cells can actively participate in T-cell mediated immune
responses by directing the magnitude and quality of the
T cell response to foreign and self-antigens [31, 32].
Here, using XLA patients as a unique human model in
absence of B cells, we, for the first time, administrated
TIV to XLA patients and evaluated the induction of
virus-specific CD4 and CD8 T cells by vaccine. We
found that both influenza virus-specific CD4+ and
CD8+ T cells can be induced by TIV in XLA patients,
and the levels and the duration of maintaining these
virus-specific cells in XLA patients are comparable to
that in normal controls. Our data indicated that the
absence of B cells does not affect the generation and
maintenance of influenza virus-specific memory T cells.
Indeed, a previous study also showed a normal hepatitis
B envelope Ag-specific CD4+ T cell memory response
in a cohort of nine XLA patients after HBV vaccination
[33]. Of note, as all these XLA patients received regular
IVIG replacement therapy, we cannot exclude the
Fig. 5 Induction of influenza virus M158–66 epitope-specific memory
CTLs by TIV in XLA patient. PBMCs from HLA-A2-seropositive XLA
patients and normal controls were isolated before and after influenza
vaccination at indicated time. HLA-A2/M158–66 tetramer staining was
performed and analyzed by flow cytometry. The numbers showed here
indicated the frequency of HLA-A2/M158–66 tetramer
+ cells within the
population of CD3+CD8+ Tcells. The data from oneXLA patient and two
normal controls with detectable HLA-A2/M158–66 tetramer
+ cells were
shown
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possibility that natural antibodies are involved in the
generation and maintenance of virus-specific memory
T cells.
Here, we further showed that TIV induced HLA-A2/
M158–66-tetramer
+ CTLs in 14% of HLA-A2-positive
XLA patients and normal individuals respectively, and
these induced epitope-specific memory CTLs can maintain up
to 3 or 6 months after vaccination in XLA patients or normal
controls. Consistent with our data, previous studies also
showed that TIV could induce HLA-A2/M158–66-tetramer
+
CTLs in 12% to 25% of HLA-A2-positive normal individuals
[34, 35]. Importantly, no obvious side effect of TIV in XLA
patients was observed. Our data suggest that influenza vaccine
is able to induce some protection against influenza virus
infection for XLA patients even though no protective anti-
bodies can be generated. Live attenuated influenza vaccine
(LAIV) is expected to induce Tcell responses more efficiently
than inactivated influenza vaccine, as it contains all the viral
internal proteins. In fact, the frequency of influenza A virus-
specific CD4 and CD8 T cells significantly increased after
LAIV but not TIV immunization in children aged 5 to 9 years
[36]. This suggests that LAIV might have more benefits than
TIV in providing T cell-mediated protection against influenza
virus in XLA patients, and this needs to be further confirmed
by a well-designed case–control study in the future.
In conclusion, we have demonstrated that XLA patients
have a normal DC and Tcell response to influenza virus and B
cells are dispensable for the generation and maintenance of
influenza virus-specific memory T cells. Our data suggest that
TIV is safe and could be an option for providing T cell-
mediated protection against influenza virus infection in XLA
patients. These data may also provide some valuable insights
to the management and general vaccine strategy to alleviate
illness severity for this particular group of immunodeficient
patients.
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